• Increased liver fat and abdominal fat may increase risk of heart disease and other serious health problems.
• Measuring liver and belly fat may identify obese people at risk of developing abnormal cholesterol.
• For some obese people, fat is not metabolically detrimental.
DALLAS – Obese people with high levels of abdominal fat and liver fat may face increased risks for heart disease and other serious health problems, according to research published in Arteriosclerosis, Thrombosis and Vascular Biology: Journal of the American Heart Association.
Obesity is commonly associated with heart disease risk and problems called cardiometabolic abnormalities, including insulin resistance, type 2 diabetes, cholesterol disorders, hypertension and gout.
Researchers in Sweden and Finland found that obese people at the highest risk have increased secretion of liver lipids, more abdominal fat and impaired removal of triglycerides from the blood stream. As such, doctors should routinely check obese patients for intra-abdominal obesity and indications of liver fat, researchers said.
“It is important to recognize that measuring abdominal fat and liver fat can identify the patients at high risk for metabolic abnormalities and heart disease,” said Jan Boren, M.D., Ph.D., study senior author and professor of molecular and clinical medicine at the University of Gothenburg in Sweden. “Such exams are important because up to 20 percent of the obese appear to be “metabolically normal.”
The researchers investigated what makes some obese people develop lipid disorders. They found that liver fat is strongly associated with increased secretion of very-low-density lipoproteins (VLDL), which contain the highest amount of triglycerides. High levels of triglycerides carry an increased risk of metabolic abnormalities and increased risk of heart disease and premature death.
“Increased liver fat is dangerous, as it is linked with many known heart disease risk factors,” said Marja-Riitta Taskinen, M.D., Ph.D. study co-author and professor of medicine at the University of Helsinki in Finland. “Lifestyle modifications such as exercise and weight loss can reduce liver fat and the secretion of lipoproteins.”
In the study, middle-aged Caucasian Finnish men were divided into three groups: 14 obese men had high triglycerides; 14 obese men had normal triglycerides and 10 men who were not obese and had normal triglycerides served as controls. The obese men’s average age was 52 to 55 years. The non-obese men’s average age was 48 years.
Researchers used proton magnetic resonance spectroscopy to measure liver fat, while subcutaneous abdominal and visceral fat were measured by magnetic resonance imaging.
The results showed that triglyceride levels in the obese men were higher as a result of the increased secretion coupled with severely impaired clearance of triglyceride-rich VLDL particles. Researchers also found:
• The obese men with elevated triglycerides had a liver fat content of 13 percent.
• The obese men with normal triglycerides had a 6.9 percent liver fat content.
• The non-obese men had a 2.9 percent liver fat content.
Researchers plan to conduct a similar study in women.
Other co-authors are: Martin Adiels, Ph.D.; Jukka Westerbacka, M.D., Ph.D.; Sanni Soderllund, M.D.; Juhani Kahri, M.D., Ph.D.; Nina Lundbom, M.D., Ph.D.; Jesper Lundbom, M.S.; Antti Hakkaarain, B.S.; Swen-Olof Olofsson, M.D., Ph.D. and Marja Ortho-Melander, Ph.D.
Author disclosures and sources of funding are on the manuscript.
Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association’s policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.americanheart.org/corporatefunding.
NR11 – 1101 (ATVB/Boren/Taskinen)
• Downloadable stock footage, animation and our image gallery are located at www.heart.org/news under Multimedia.
• Obesity information
• CVD risk assessment tools
• For more information about nutrition and heart health visit the American Heart Association’s Nutrition Center at www.heart.org/nutrition.